| 多发性骨髓瘤的靶向治疗 |
| |
| 引用本文： | 陈文明. 多发性骨髓瘤的靶向治疗[J]. 白血病．淋巴瘤, 2009, 18(9): 523-528. DOI: 10.3760/cma.j.issn.1009-9921.2009.09.004 |
| |
| 作者姓名： | 陈文明 |
| |
| 作者单位： | 北京市多发性骨髓瘤医疗研究中心首都医科大学附属北京朝阳医院血液科,100020 |
| |
| 摘 要： | 在过去的近10年中，尽管多发性骨髓瘤（MM）的治疗取得了较大进步，患者的缓解率明显提高，但总的生存期（OS）没有明显改善。随着对MM发病机制研究的深入，以沙利度胺和硼替佐米为代表的靶向治疗药物的应用，使MM的完全缓解率明显提高，OS得到延长，MM成为一种趋于治愈性的疾病。
|
| 关 键 词： | 多发性骨髓瘤 靶向治疗 |
| 收稿时间： | 2009-09-08; |
Target treatment of multiple myeloma |
| |
| Wenming CHEN. Target treatment of multiple myeloma[J]. Journal of Leukemia & Lymphoma, 2009, 18(9): 523-528. DOI: 10.3760/cma.j.issn.1009-9921.2009.09.004 |
| |
| Authors: | Wenming CHEN |
| |
| Abstract: | In the past decades,the response rate of multiple myelorna(MM)to chemotherapy has been rapidly improved,but the complete remission(CR)was still low,and the overall survival(OS)was still short.As the usage of thalidomide and bortezomib,CR is improved and OS is extended.It is regarded that MM is a cancer which could be possibly cured.In this article,the target therapy of MM Was reviewed. |
| |
| Keywords: | Multiple myeloma Target treatment |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《白血病．淋巴瘤》浏览原始摘要信息 |
|
点击此处可从《白血病．淋巴瘤》下载免费的PDF全文 |
